Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56


Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology.

Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):57-67. Review.


Searching for valid psychiatric phenotypes: discrete latent variable models.

Leoutsakos JM, Zandi PP, Bandeen-Roche K, Lyketsos CG.

Int J Methods Psychiatr Res. 2010 Jun;19(2):63-73. doi: 10.1002/mpr.301.


One size fits all? Why we need more sophisticated analytical methods in the explanation of trajectories of cognition in older age and their potential risk factors.

Terrera GM, Brayne C, Matthews F; CC75C Study Collaboration Group.

Int Psychogeriatr. 2010 Mar;22(2):291-9. doi: 10.1017/S1041610209990937. Epub 2009 Nov 12.


Structural neuroimaging in the detection and prognosis of pre-clinical and early AD.

Fennema-Notestine C, McEvoy LK, Hagler DJ Jr, Jacobson MW, Dale AM; The Alzheimer's Disease Neuroimaging Initiative.

Behav Neurol. 2009;21(1):3-12. doi: 10.3233/BEN-2009-0230. Review.


Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling.

Muthén B, Brown HC.

Stat Med. 2009 Nov 30;28(27):3363-85. doi: 10.1002/sim.3721.


Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort.

Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB.

Neurology. 2009 Jun 2;72(22):1899-905. doi: 10.1212/WNL.0b013e3181a18691. Epub 2009 Apr 22.


Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.

ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC.

Alzheimers Dement. 2009 Mar;5(2):93-104. doi: 10.1016/j.jalz.2008.09.004.


Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF.

Ann Neurol. 2008 Nov;64(5):492-8. doi: 10.1002/ana.21509.


Frequent amyloid deposition without significant cognitive impairment among the elderly.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE.

Arch Neurol. 2008 Nov;65(11):1509-17. doi: 10.1001/archneur.65.11.1509.


Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.

Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S.

Neuroimage. 2008 Nov 15;43(3):430-9. doi: 10.1016/j.neuroimage.2008.07.053. Epub 2008 Aug 12.


Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment.

Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM.

Arch Neurol. 2008 Sep;65(9):1231-6. doi: 10.1001/archneurol.2008.1.


Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology.

Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P.

Curr Pharm Des. 2008;14(14):1419-27. Review.


Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology.

Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, Evans DA, Bennett DA.

Neurology. 2008 Jun 3;70(23):2219-25. doi: 10.1212/01.wnl.0000313813.48505.86.


No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies.

Szekely CA, Green RC, Breitner JC, Østbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP.

Neurology. 2008 Jun 10;70(24):2291-8. doi: 10.1212/01.wnl.0000313933.17796.f6. Epub 2008 May 28.


Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies.

Lyketsos CG, Szekely CA, Mielke MM, Rosenberg PB, Zandi PP.

Int Psychogeriatr. 2008 Oct;20(5):871-89. doi: 10.1017/S1041610208007382. Epub 2008 May 23. Review.


Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M.

Arch Neurol. 2008 Jul;65(7):896-905. doi: 10.1001/archneur.2008.65.7.nct70006. Epub 2008 May 12.


Protective effects of NSAIDs on the development of Alzheimer disease.

Vlad SC, Miller DR, Kowall NW, Felson DT.

Neurology. 2008 May 6;70(19):1672-7. doi: 10.1212/01.wnl.0000311269.57716.63.


Trajectory of mild cognitive impairment onset.

Howieson DB, Carlson NE, Moore MM, Wasserman D, Abendroth CD, Payne-Murphy J, Kaye JA.

J Int Neuropsychol Soc. 2008 Mar;14(2):192-8. doi: 10.1017/S1355617708080375.


No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial.

de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, Kremer B.

PLoS One. 2008 Jan 23;3(1):e1475. doi: 10.1371/journal.pone.0001475.


Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.

AD2000 Collaborative Group, Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J.

Lancet Neurol. 2008 Jan;7(1):41-9.


Supplemental Content

Support Center